| Literature DB >> 29348397 |
Dong-Hwan Jung1, Cheon-Soo Park2, Tae-Yong Ha1, Gi-Won Song1, Gil-Chun Park1, Yong-Pil Cho1, Sung-Gyu Lee1.
Abstract
BACKGROUND The aim of this study was to assess the impact of placement of an aortohepatic conduit on graft and patient survival after liver transplantation (LT) in selected patients with an inadequate recipient hepatic artery (HA) for a standard arterial anastomosis. MATERIAL AND METHODS Of 331 patients who underwent deceased donor LT, 25 (7.6%) who received placement of an aortohepatic conduit at the time of transplantation were included. Clinical characteristics and outcomes, including postoperative complications, conduit patency, and graft and patient survival rates, were analyzed. RESULTS All 25 patients included in this study presented a high preoperative Model for End-stage Liver Disease score (25.4±8.6; range, 6-42) and high rates of retransplantation (n=11, 44%) or previous abdominal - pelvic surgery (n=5, 20%). The observed postoperative vascular complications were portal vein thrombosis in 3 cases (12%) and anastomosis-site bleeding of the aortohepatic conduit in 1 case (4%); there was no HA thrombosis or stenosis in our analysis. With a median follow-up of 37 months (range, 0-69 months), all aortohepatic conduits were patent, and the graft and patient survival rates were 84% and 68%, respectively. The causes of death were graft failure (n=4), pneumonia (n=3), and cerebrovascular accidents (n=1). CONCLUSIONS Our results indicate that placement of an aortohepatic conduit is a feasible alternative to a standard arterial anastomosis in selected patients whose HA and surrounding potential inflow arteries are not suitable for standard arterial anastomosis.Entities:
Mesh:
Year: 2018 PMID: 29348397 PMCID: PMC6248308 DOI: 10.12659/aot.906307
Source DB: PubMed Journal: Ann Transplant ISSN: 1425-9524 Impact factor: 1.530
Figure 1Schematic diagram of the surgical procedure. AIA – deceased donor aorto-iliac arterial segment; CHA – common hepatic artery; GD – gastroduodenal artery.
Clinical characteristics of the study population.
| Patients (n=25) | |
|---|---|
| Mean age (years) | 51.5±10.3 (28–69) |
| Male sex | 14 (56) |
| Body mass index (kg/m2) | 20.9±2.4 (17.0–26.3) |
| Previous abdominal–pelvic surgery | 16 (64) |
| Indications for liver transplantation | |
| Retransplantation | 11 (44) |
| HBV-LC without HCC | 5 (20) |
| HBV-LC with HCC | 4 (16) |
| Others | 5 (20) |
| MELD score | 25.4±8.6 (6–42) |
| Preoperative hospital days | 30.8±24.2 (0–95) |
| Postoperative hospital days | 59.3±43.0 (2–165) |
| Operative findings | |
| Operative time (min) | 703.2±142.8 (451–1058) |
| RBC transfusion (packs) | 27.6±19.3 (6–75) |
| FFP transfusion (packs) | 25.5±20.3 (6–90) |
| Cold ischemia time (min) | 248.7±84.9 (79–423) |
| Warm ischemia time (min) | 47.9±14.3 (25–90) |
Continuous data are expressed as means ± standard deviations (range) and categorical data as numbers (%).
HBV-LC – hepatitis B cirrhosis; HCC – hepatocellular carcinoma; MELD – Model for End-stage Liver Disease; RBC – red blood cells; FFP – fresh frozen plasma.
Included three recipients with previous chemoembolization procedures.
Posttransplantation clinical outcomes of the study population.
| Early (≤1 month after LT) | Total | |
|---|---|---|
| Conduit patency | 25 (100) | 25 (100) |
| Graft survival | 23 (92) | 21 (84) |
| Patient survival | 21 (84) | 17 (68) |
| Cause of death | ||
| Graft failure | 2 (8) | 4 (16) |
| Pneumonia, sepsis | 2 (8) | 3 (12) |
| CVA | 0 | 1 (4) |
Values are presented as numbers of patients (%). LT – liver transplantation; CVA – cerebrovascular accidents.
During a median follow-up of 37 months (range, 0–69 months).